Champlain Investment Partners LLC Raised Stake in Integra Lifesciences Holdings (IART) by $4.40 Million

Investors sentiment increased to 1.32 in Q2 2019. Its up 0.05, from 1.27 in 2019Q1. It increased, as 20 investors sold IART shares while 65 reduced holdings. 39 funds opened positions while 73 raised stakes. 68.86 million shares or 0.56% less from 69.24 million shares in 2019Q1 were reported. Oregon Employees Retirement Fund accumulated 0.02% or 28,654 shares. Pure Advsrs Inc, California-based fund reported 10,781 shares. The North Carolina-based Carroll Assoc has invested 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). 16,762 are held by Dupont Capital Mgmt Corporation. Stanley holds 0.05% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 4,000 shares. Morgan Stanley holds 0% or 27,302 shares in its portfolio. Hrt Ltd Limited Liability Company reported 13,028 shares stake. Hood River Cap Mngmt Lc, Oregon-based fund reported 602,226 shares. The New York-based Alliancebernstein LP has invested 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Price T Rowe Assocs Md has invested 0% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Cambridge holds 19,080 shares. Virginia Retirement Systems Et Al, Virginia-based fund reported 19,300 shares. Moreover, Texas Permanent School Fund has 0.04% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 48,149 shares. Northern reported 685,098 shares. Parametric Portfolio Associates Limited Liability Co holds 110,522 shares.

Champlain Investment Partners Llc increased its stake in Integra Lifesciences Holdings (IART) by 1.98% based on its latest 2019Q2 regulatory filing with the SEC. Champlain Investment Partners Llc bought 88,031 shares as the company’s stock rose 24.59% . The institutional investor held 4.54 million shares of the laboratory analytical instruments company at the end of 2019Q2, valued at $228.96 million, up from 4.45 million at the end of the previous reported quarter. Champlain Investment Partners Llc who had been investing in Integra Lifesciences Holdings for a number of months, seems to be bullish on the $5.20B market cap company. The stock increased 2.89% or $1.71 during the last trading session, reaching $60.84. About 315,967 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 3.56% since October 12, 2018 and is uptrending. It has outperformed by 3.56% the S&P500.

Champlain Investment Partners Llc, which manages about $6.04 billion and $8.47B US Long portfolio, decreased its stake in Brady Corporation Class A (NYSE:BRC) by 102,299 shares to 726,780 shares, valued at $27.58M in 2019Q2, according to the filing. It also reduced its holding in Wex Inc. (NYSE:WEX) by 500,401 shares in the quarter, leaving it with 1.26 million shares, and cut its stake in Icu Medical Inc. (NASDAQ:ICUI).

More notable recent Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were published by: Globenewswire.com which released: “Integra LifeSciences Announces the Approval of DuraGenĀ® in Japan – GlobeNewswire” on March 14, 2019, also Finance.Yahoo.com with their article: “Integra Lifesciences’ (IART) Earnings Top Estimates in Q2 – Yahoo Finance” published on July 25, 2019, Benzinga.com published: “The Week Ahead In Biotech: Pharma Earnings Pick Up Pace – Benzinga” on July 20, 2019. More interesting news about Integra LifeSciences Holdings Corporation (NASDAQ:IART) were released by: Nasdaq.com and their article: “Health Care Sector Update for 05/11/2016: IART – Nasdaq” published on May 11, 2016 as well as Globenewswire.com‘s news article titled: “Integra LifeSciences Announces Promotion of Glenn Coleman to Newly-Created Role of Chief Operating Officer and Appointment of Carrie Anderson as Chief Financial Officer – GlobeNewswire” with publication date: June 24, 2019.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.